IL17A and Parkinson disease: It has been reported that IL-17A exacerbates dopaminergic neuronal loss only in the presence of microglia and IL-17A-treated microglial medium facilitates dopaminergic neuronal death, suggesting that IL-17A accelerates neurodegeneration in Parkinson’s disease depending on microglial activation [42].